查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1803870

非鴉片類藥物治療市場（依藥物類型、給藥途徑、應用、最終用途和分銷管道）－2025-2030 年全球預測

Non-Opioid Therapeutics Market by Drug Type, Route of Administration, Application, End Use, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

非鴉片類藥物治療市場預計到 2024 年將達到 407.7 億美元，2025 年將達到 437.8 億美元，到 2030 年將達到 629 億美元，複合年成長率為 7.49%。

主要市場統計數據
基準年2024年 407.7億美元
預計2025年 437.8億美元
預測年份 2030 629億美元
複合年成長率（%） 7.49%

透過先進的分子標靶、以患者為中心的解決方案和協作創新改變疼痛管理，開啟非鴉片類藥物治療的新時代

隨著非鴉片類藥物療法成為醫學創新的前沿，疼痛管理的改變正發生根本性轉變。這種快速成長的驅動力源自於尖端分子研究、以病人為中心的照護模式以及注重安全性和有效性的全球法規環境。透過擺脫傳統的鴉片類藥物依賴，該行業正在為有望降低成癮風險並保持可靠臨床療效的新型治療方法鋪平道路。

揭示了透過新模式、監管調整和數位健康整合重新定義非鴉片類藥物治療格局的變革性變化

目前的非鴉片類藥物治療格局正因變革性轉變而再形成，這些變革包括新模式、監管調整和技術整合。例如，新一代離子通道調變器和胜肽類療法的興起正在重新定義藥理套件。同時，主要市場的監管機構已發布更新指南，簡化了那些與管制藥物相比具有良好安全邊際的治療方法的加速核准。

全面分析2025年美國關稅對非鴉片類藥物供應鏈、定價結構與全球貿易動態的影響

2025年美國關稅的實施，給支持非鴉片類藥物研發和分銷的全球供應鏈帶來了巨大壓力。依賴進口原料藥的製造商面臨採購成本上升的困境，這促使他們重新評估其供應商關係和近岸外包策略。為此，一些中型製造商已啟動在地採購協議，以確保業務的連續性和成本的可預測性。

透過藥物類型、給藥途徑、臨床用途、最終用途和分銷管道等關鍵見解，繪製非鴉片類藥物治療市場格局

透過按藥物類型細分，我們發現對乙醯胺酚衍生物仍然是急性疼痛緩解的基石，而抗憂鬱症機制的進展正在揭示慢性疼痛緩解的新途徑。與抗癲癇藥物的發展同步，神經病變疼痛管理的應用也有望得到推廣，局部麻醉劑的創新也正在增強手術全期護理。新一代非類固醇消炎劑的配方提高了胃腸道耐受性，並將繼續廣泛應用於各種發炎疾病。

探索美洲、中東和非洲以及亞太地區的區域動態，這些動態將影響市場滲透、患者獲取和成長機會

在美洲，監管機構正在協調核准流程，核准具有非成癮性的療法，培育強大的臨床研發管線，並吸引創業投資。醫療保健報銷模式正日益包容非鴉片類藥物替代品，患者權益組織正在影響政策，以擴大創新治療方法的可及性。這一區域性勢頭正在加速產品上市，並為綜合疼痛管理試驗計畫創造肥沃的土壤。

與領先的行業參與者建立創新夥伴關係，推動非鴉片類藥物治療領域的研發和商業化

業界領導企業正在採取多管齊下的策略，以保持其在非鴉片類藥物治療領域的競爭優勢。擁有強大研發實力的全球製藥公司正在透過內部藥物發現專案和定向收購生物技術創新公司來擴大其產品組合。同時，非鴉片類藥物專家正在與學術中心和受託研究機構建立夥伴關係，以加速轉化研究。

為產業領導者提供策略性和可操作性的建議，以加強合作、加速創新並應對非鴉片類藥物治療領域的監管複雜性

產業領導者應優先建立策略聯盟，將學術研究與商業開發連接起來，以加速研發管線的推進。透過利用共用的專業知識和資源池，各組織可以降低早期風險並加強候選藥物的檢驗。同時，組成聯盟倡導統一的監管標準，可以簡化核准途徑並加快上市時間。

市場分析所依據的全面二手資料調查方法的詳細資訊，包括初步訪談、二手資料檢驗和專家小組評審

分析基於穩健的多元調查方法，結合了一手資料和二手資訊來源。一手資料研究包括對製藥、生物技術和醫療保健提供者高階主管的深入訪談，以及與監管專家和關鍵意見領袖的對話，以檢驗新興趨勢和策略重點。

結論強調了非鴉片類藥物療法在滿足未滿足需求、推動永續成長和改​​善全球患者治療效果方面的變革潛力

非鴉片類藥物治療的普及之路以技術創新、策略合作和不斷變化的監管格局為特徵。隨著相關人員圍繞著通用目標——降低鴉片類藥物成癮——攜手合作，該領域正經歷著新型分子實體、數位健康整合和以患者為中心的醫療模式的空前繁榮。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 利用下一代脂質體遞送系統控制局部疼痛的新興局部抗發炎製劑
  • 拓展新型鈉通道阻斷劑用於治療老年人慢性神經病變疼痛
  • 加速監管核准，促進用於緩解術後疼痛的新型膽囊收縮素受體調節劑的開發
  • 虛擬實境與數位療法在復健環境中的非鴉片類鎮痛治療的應用
  • 利用基於轉錄組的生物標記實現非鴉片類鎮痛治療的個人化並改善臨床療效
  • 增加針對神經生長因子的單株抗體的投資，用於治療骨關節炎和背痛
  • 生技公司與數位醫療公司建立策略夥伴關係，加速非鴉片類疼痛管理解決方案的開發

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 非鴉片類治療藥物市場（依藥物類型）

  • 乙醯胺酚
  • 抗憂鬱症
  • 抗癲癇藥物
  • 局部麻醉劑
  • 非類固醇消炎劑

9. 非鴉片類藥物治療市場（依給藥途徑）

  • 靜脈
  • 口服
  • 直腸

第10章非鴉片類藥物治療市場（依應用）

  • 癌症相關疼痛
  • 慢性疼痛
  • 發炎性疾病
  • 偏頭痛
  • 神經退化性疾病

11. 非鴉片類藥物治療市場（依最終用途）

  • 門診手術中心
  • 診斷中心
  • 居家照護環境
  • 醫院和診所

第 12 章非鴉片類藥物治療市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

13.美洲非鴉片類藥物治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲非鴉片類藥物治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區非鴉片類藥物治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • GlaxoSmithKline plc
    • Acorda Therapeutics, Inc.
    • Allay Therapeutics Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Biogen Inc.
    • Centrexion Therapeutics,
    • Concentric Analgesics, Inc.
    • Confo Therapeutics NV
    • Durect Corporation
    • Eli Lilly and Company
    • Latigo Biotherapeutics, Inc.
    • Lexicon Pharmaceuticals, Inc.
    • Liquidia Corporation
    • McNeil-PPC, Inc. by Johnson & Johnson Inc.
    • Mylan NV by Viatris Inc.
    • Neumentum Inc.
    • SiteOne Therapeutics, Inc.
    • Sun Pharmaceutical Industries Limited
    • Tris Pharma, Inc.
    • Vertex Pharmaceuticals Incorporated
    • Pfizer Inc.
    • Amgen Inc.
    • Cara Therapeutics, Inc.
    • Bioelectronics Corporation

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-4772A753AA73

The Non-Opioid Therapeutics Market was valued at USD 40.77 billion in 2024 and is projected to grow to USD 43.78 billion in 2025, with a CAGR of 7.49%, reaching USD 62.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 40.77 billion
Estimated Year [2025] USD 43.78 billion
Forecast Year [2030] USD 62.90 billion
CAGR (%) 7.49%

Pioneering a New Era in Non-Opioid Therapeutics through Advanced Molecular Targets, Patient-Centric Solutions, and Collaborative Innovation to Transform Pain Management

The evolution of pain management is undergoing a fundamental shift as non-opioid therapeutics ascend to the forefront of medical innovation. This surge is rooted in the convergence of advanced molecular research, patient-centered care models, and a global regulatory environment that prioritizes safety and efficacy. By moving beyond traditional opioid reliance, the industry is opening avenues for novel therapeutic modalities that promise to reduce dependency risks while maintaining robust clinical outcomes.

As a result, stakeholders across the value chain are collaborating to harness the potential of targeted small molecules, biologics, and innovative drug delivery systems. These efforts reflect a broad commitment to addressing chronic pain, inflammatory disorders, and neurodegenerative conditions with modalities that can offer comparable relief to opioids but with enhanced safety profiles. Moreover, advancements in biomarkers and genomics are enabling more personalized treatment strategies, aligning with the growing demand for precision medicine.

Consequently, the non-opioid therapeutics sector is positioned for a transformative trajectory. From early-stage research to late-phase clinical trials, the integration of cross-disciplinary expertise is driving accelerated innovation. As this introductory analysis establishes, the industry's renewed focus on collaborative research, regulatory alignment, and patient wellbeing lays a solid foundation for sustained growth and long-term impact.

Unveiling the Transformative Shifts Redefining the Non-Opioid Therapeutics Landscape with Emerging Modalities, Regulatory Realignments, and Digital Health Integration

The current landscape of non-opioid therapeutics is being reshaped by transformative shifts that encompass emerging modalities, regulatory realignments, and technology integration. For instance, the rise of next-generation ion channel modulators and peptide-based therapies is redefining the pharmacological toolkit. In parallel, regulatory bodies in key markets have issued updated guidelines that streamline expedited pathways for therapies demonstrating favorable safety margins compared to controlled substances.

Furthermore, digital health applications and remote monitoring platforms are enhancing treatment adherence and enabling real-time patient feedback, which, in turn, inform continuous improvement in therapeutic protocols. This digital infusion is complementing pharmacological advances by facilitating more nuanced patient engagement and outcome measurement. As a result, healthcare providers are increasingly adopting integrated care models that bridge pharmacotherapy with digital support services.

In addition, strategic alliances between academic institutions, mid-sized biotechnology firms, and contract research organizations are accelerating preclinical to clinical transitions. By leveraging shared resources and multidisciplinary expertise, these collaborations are reducing development timelines while maintaining rigorous scientific validation. These collective initiatives are driving the paradigm shift from opioid-centric pain management toward diversified, non-addictive therapeutic approaches.

Analyzing the Comprehensive Impact of the 2025 United States Tariffs on Non-Opioid Therapeutics Supply Chains, Pricing Structures, and Global Trade Dynamics

The introduction of the 2025 United States tariffs has exerted significant pressure on the global supply chains underpinning non-opioid therapeutic development and distribution. Manufacturers reliant on imported active pharmaceutical ingredients have faced elevated procurement costs, prompting a reevaluation of supplier relationships and nearshoring strategies. In response, several mid-sized producers have initiated localized sourcing agreements to safeguard continuity and cost predictability.

Meanwhile, pricing structures throughout the distribution network have adjusted to reflect the altered cost base, affecting both contract negotiations with large health systems and procurement practices at retail outlets. This shift has underscored the importance of dynamic pricing strategies that balance margin protection with accessibility for end users. Consequently, organizations are deploying advanced analytics to model tariff pass-through scenarios and to optimize channel-specific pricing architectures.

Concurrently, global trade dynamics have prompted companies to diversify manufacturing footprints across multiple jurisdictions. Establishing secondary production nodes in regions with favorable trade agreements has mitigated exposure to unilateral tariff increases. As a result, resilience planning now occupies a central role in strategic roadmaps, ensuring that the non-opioid therapeutics sector remains agile amid evolving geopolitical landscapes.

Deriving Key Insights from Drug Type, Administration Route, Clinical Application, End Use, and Distribution Channel to Map the Non-Opioid Therapeutics Market Landscape

Insights derived from drug type segmentation reveal that acetaminophen derivatives remain a cornerstone for acute pain relief, while advancements in antidepressant mechanisms are unlocking new pathways for chronic pain modulation. Parallel developments in antiepileptics are showing promise for neuropathic pain management, and innovations in local anesthetics are enhancing perioperative care. Nonsteroidal anti-inflammatory drugs continue to serve a broad spectrum of inflammatory indications, with next-generation formulations improving gastrointestinal tolerability.

When evaluating route of administration and application segments, the intravenous channel has gained traction for rapid-onset interventions in hospital settings, whereas oral therapies offer convenience and adherence in chronic care scenarios. Rectal delivery, though less prominent, persists as an alternative for patients requiring non-oral dosing. In terms of clinical focus, cancer related pain management is benefitting from multimodal regimens that integrate pharmacological and supportive therapies. Chronic pain protocols are evolving with combination approaches that leverage centrally acting agents. Inflammatory disorders, migraine relief, and neurodegenerative pain syndromes are all seeing targeted therapeutic designs informed by enhanced pathophysiological understanding.

Examining end use and distribution channels underscores the growing role of ambulatory surgical centers and diagnostic centers in outpatient pain management. Home care settings are expanding as telehealth-enabled nursing services provide continuous support. Hospitals and clinics remain critical for acute intervention. Meanwhile, hospital pharmacies lead in dispensing specialized non-opioid formulations. Online pharmacies are driving accessibility for maintenance therapies, and retail pharmacies continue to serve as the primary point of contact for over-the-counter anti-inflammatory and analgesic products.

Exploring Distinct Regional Dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific Shaping Market Penetration, Patient Access, and Growth Opportunities

In the Americas, regulatory agencies have harmonized approval processes to prioritize therapeutics demonstrating non-addictive profiles, fostering robust clinical pipelines and encouraging venture capital investment. Healthcare reimbursement models are increasingly accommodating non-opioid alternatives, and patient advocacy groups are influencing policy to expand access to innovative therapies. This regional momentum is accelerating product launches and creating a fertile ground for pilot programs in integrated pain management.

Across Europe, the Middle East & Africa, stakeholders face a diverse tapestry of regulatory frameworks and reimbursement structures. In Western Europe, strong pharmacovigilance measures and centralized approval systems are driving the adoption of novel compounds. Meanwhile, in select Middle Eastern and African markets, growing demand for cost-effective non-opioid options is inspiring local manufacturing initiatives. Cross-border collaborations and public-private partnerships are critical in addressing infrastructure gaps and streamlining distribution pathways.

The Asia-Pacific region is witnessing rapid growth underpinned by rising healthcare expenditure and expanding hospital networks. Regulatory authorities in key markets have introduced fast-track designations for therapies addressing opioid dependence. Additionally, digital health ecosystems are maturing, enabling better patient monitoring and adherence tracking. Regional manufacturing clusters are also emerging as strategic export hubs, further integrating Asia-Pacific into global supply chains.

Illuminating Leading Industry Players and Innovative Partnerships Driving Research, Development, and Commercialization in the Non-Opioid Therapeutics Sector

Leading industry players are adopting multifaceted strategies to maintain competitive advantage in the non-opioid therapeutics arena. Global pharmaceutical companies with extensive R&D capabilities are expanding their portfolios through internal discovery programs and targeted acquisitions of biotech innovators. At the same time, dedicated non-opioid specialists are forging partnerships with academic centers and contract research organizations to accelerate translational research.

Beyond traditional pharma, technology-driven start-ups are integrating digital biomarkers and artificial intelligence to optimize dosing regimens and predict patient response. This convergence of software and pharmacology is redefining value propositions and enabling more nuanced differentiation among therapeutic candidates. In parallel, manufacturing service providers are investing in flexible production platforms capable of handling peptide-based therapies and other complex molecules, thereby meeting the evolving demands of their pharmaceutical clients.

Collectively, these strategic movements underscore a sectorwide commitment to innovation, quality, and patient-centric outcomes. Enhanced collaboration between established players and nimble innovators is catalyzing a synergistic ecosystem where each participant contributes unique expertise toward the shared goal of delivering effective non-opioid solutions.

Presenting Strategic, Actionable Recommendations for Industry Leaders to Enhance Collaboration, Accelerate Innovation, and Navigate Regulatory Complexities in Non-Opioid Therapeutics

Industry leaders should prioritize strategic alliances that bridge academic research with commercial development to accelerate pipeline progression. By leveraging shared expertise and resource pools, organizations can mitigate early-stage risks and enhance candidate validation. Simultaneously, forming consortia that advocate for harmonized regulatory standards will streamline approval pathways and reduce time to market.

Investing in advanced analytics and digital health solutions is another critical recommendation. Implementing real-world evidence platforms will enable continuous post-launch monitoring of safety and efficacy, thereby reinforcing stakeholder confidence. Moreover, integrating patient engagement tools can improve adherence rates and inform iterative product enhancements.

Supply chain resilience must remain a focal point. To this end, diversifying sourcing strategies and establishing backup manufacturing nodes will minimize the disruptive impact of geopolitical shifts and tariff fluctuations. Finally, fostering a culture of cross-functional collaboration-uniting R&D, regulatory affairs, commercial teams, and patient advocacy groups-will ensure that therapeutic offerings are aligned with evolving clinical needs and market dynamics.

Detailing the Comprehensive Multi-Source Research Methodology Underpinning the Market Analysis, Incorporating Primary Interviews, Secondary Data Validation, and Expert Panel Reviews

This analysis is underpinned by a robust, multi-phase research methodology combining primary and secondary data sources. Primary research involved in-depth interviews with senior executives across pharmaceutical, biotechnology, and healthcare provider organizations, alongside discussions with regulatory experts and key opinion leaders to validate emerging trends and strategic priorities.

Secondary research encompassed a comprehensive review of peer-reviewed journals, conference proceedings, patent filings, regulatory agency publications, and industry whitepapers to build a foundational understanding of technological, clinical, and policy developments. Data triangulation techniques were employed to ensure consistency and accuracy across disparate information streams.

Expert panel reviews provided additional validation, enabling refinement of thematic insights and strategic imperatives. Quantitative and qualitative findings were synthesized to produce a nuanced, evidence-based narrative that reflects both macro-level dynamics and granular operational considerations.

Concluding Remarks Emphasizing the Transformative Potential of Non-Opioid Therapeutics to Meet Unmet Needs, Drive Sustainable Growth, and Improve Patient Outcomes Globally

The journey toward widespread adoption of non-opioid therapeutics is marked by innovation, strategic collaboration, and evolving regulatory landscapes. As stakeholders align around the shared imperative to reduce opioid dependency, the sector is witnessing an unprecedented surge in novel molecular entities, digital health integrations, and patient-centric care models.

Regional dynamics and tariff implications underscore the need for adaptive strategies that balance cost resilience with market expansion. Segmentation insights reveal targeted opportunities across drug types, administration routes, clinical applications, and distribution channels. Leading companies are leveraging partnerships, technological capabilities, and manufacturing flexibility to capture these opportunities, while actionable recommendations emphasize the importance of cross-functional collaboration and advanced analytics.

Ultimately, the non-opioid therapeutics sector is poised to transform pain management paradigms and improve patient outcomes globally. By harnessing these insights, industry participants can make informed decisions that drive meaningful progress and sustainable growth in this critical therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Emergence of topical anti inflammatory formulations utilizing next generation liposomal delivery systems for localized pain control
  • 5.2. Expansion of novel sodium channel blockers for chronic neuropathic pain management in aging populations
  • 5.3. Regulatory fast track approvals encouraging development of novel cholecystokinin receptor modulators for post operative pain relief
  • 5.4. Integration of virtual reality and digital therapeutics for non opioid pain treatment across rehabilitation settings
  • 5.5. Adoption of transcriptome-based biomarkers to personalize non opioid analgesic therapies and improve clinical outcomes
  • 5.6. Rising investment in monoclonal antibodies targeting nerve growth factor for osteoarthritis and lower back pain relief
  • 5.7. Strategic partnerships between biotech and digital health firms to accelerate non opioid pain management solutions

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Non-Opioid Therapeutics Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Acetaminophen
  • 8.3. Antidepressants
  • 8.4. Antiepileptics
  • 8.5. Local Anesthetics
  • 8.6. Nonsteroidal Anti-Inflammatory Drugs

9. Non-Opioid Therapeutics Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Rectal

10. Non-Opioid Therapeutics Market, by Application

  • 10.1. Introduction
  • 10.2. Cancer Related Pain
  • 10.3. Chronic Pain
  • 10.4. Inflammatory Disorders
  • 10.5. Migraine
  • 10.6. Neurodegenerative Disorders

11. Non-Opioid Therapeutics Market, by End Use

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Centers
  • 11.4. Home Care Settings
  • 11.5. Hospitals & Clinics

12. Non-Opioid Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Americas Non-Opioid Therapeutics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Non-Opioid Therapeutics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Non-Opioid Therapeutics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Acorda Therapeutics, Inc.
    • 16.3.4. Allay Therapeutics Inc.
    • 16.3.5. Alnylam Pharmaceuticals, Inc.
    • 16.3.6. Biogen Inc.
    • 16.3.7. Centrexion Therapeutics,
    • 16.3.8. Concentric Analgesics, Inc.
    • 16.3.9. Confo Therapeutics NV
    • 16.3.10. Durect Corporation
    • 16.3.11. Eli Lilly and Company
    • 16.3.12. Latigo Biotherapeutics, Inc.
    • 16.3.13. Lexicon Pharmaceuticals, Inc.
    • 16.3.14. Liquidia Corporation
    • 16.3.15. McNeil-PPC, Inc. by Johnson & Johnson Inc.
    • 16.3.16. Mylan N.V. by Viatris Inc.
    • 16.3.17. Neumentum Inc.
    • 16.3.18. SiteOne Therapeutics, Inc.
    • 16.3.19. Sun Pharmaceutical Industries Limited
    • 16.3.20. Tris Pharma, Inc.
    • 16.3.21. Vertex Pharmaceuticals Incorporated
    • 16.3.22. Pfizer Inc.
    • 16.3.23. Amgen Inc.
    • 16.3.24. Cara Therapeutics, Inc.
    • 16.3.25. Bioelectronics Corporation

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. NON-OPIOID THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. NON-OPIOID THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. NON-OPIOID THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. NON-OPIOID THERAPEUTICS MARKET: RESEARCHAI
  • FIGURE 26. NON-OPIOID THERAPEUTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. NON-OPIOID THERAPEUTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. NON-OPIOID THERAPEUTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NON-OPIOID THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CANCER RELATED PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CANCER RELATED PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY MIGRAINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-OPIOID THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 71. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 73. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 83. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 84. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 85. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 87. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 89. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 90. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 91. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 92. CANADA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 93. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 96. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 97. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 98. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 99. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 100. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 101. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. MEXICO NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 103. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 106. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 107. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 109. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 110. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 111. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. BRAZIL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 113. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 117. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 118. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 119. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 120. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 121. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. ARGENTINA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED KINGDOM NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 145. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 149. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 150. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 151. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 152. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 153. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. GERMANY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 155. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 159. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 161. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 162. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 163. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. FRANCE NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 165. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 169. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 171. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 172. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 173. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. RUSSIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 175. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 179. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 181. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 182. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 183. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. ITALY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 185. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 189. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 191. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 192. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 193. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. SPAIN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED ARAB EMIRATES NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 212. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 213. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. SAUDI ARABIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 219. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 221. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 222. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 223. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. SOUTH AFRICA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 225. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 229. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 231. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 232. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 233. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. DENMARK NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 242. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. NETHERLANDS NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 245. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 249. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 251. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 252. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 253. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. QATAR NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 255. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 259. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 261. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 262. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 263. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. FINLAND NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 265. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 269. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 271. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 272. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 273. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. SWEDEN NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 275. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 279. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 281. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 282. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 283. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. NIGERIA NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 285. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 289. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 292. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 293. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EGYPT NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 295. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 299. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 300. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 301. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 302. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 303. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. TURKEY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 305. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 307. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 309. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 311. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 312. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 313. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. ISRAEL NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 315. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 319. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 321. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 322. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
  • TABLE 323. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. NORWAY NON-OPIOID THERAPEUTICS MARKET SIZE, BY DIST